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Abstract: Differential diagnosis between keratoacanthoma (KA) and
squamous cell carcinoma (SCC) is difficult due to their similarities. The
mechanisms that drive their distinct biological behavior are poorly under-
stood.
To investigate whether the assessment of microvessel density (MVD)
could be helpful in KA and SCC differential diagnosis and to gain insight
into the pathogenesis of KA-like neoplasms, we compared the density of
CD105- and CD34-stained vessels in KAs and SCCs and their relation to
the expression of the p53 oncoprotein and proliferation marker Ki67.
This is an observational retrospective cohort study. Forty lesions with
clinical appearance of KAs (29 KAs and 11 SCCs) entered the study. A
biopsy was taken from each lesion at presentation and the natural clinical
course was monitored for at least 1 month. Growing or minimally
regressing lesions were submitted to complete surgical excision. The
diagnoses were established on combined clinical, histological, and
follow-up evaluations. The MVD and p53 or Ki67 expression in neo-
plastic cells were assessed through morphometry.
The MVD did not show discriminating power between KAs and
SCCs. The Ki67 proliferation rate was significantly higher in SCCs.
Although neoangiogenesis (CD105-MVD) in KAs was associated with
cell proliferation, in SCCs it was not. There was significant correlation
between p53 expression and neoplasia size in SCCs but not in KAs.
From our results, we may conclude that KA and SCC have sim-
ilarities, as CD105- and CD34-MVD. However, the low Ki67 prolifer-
ation index and the positive correlation between Ki-67 index and
neovascularization in KA suggest a dependence in neovascularization
to grow in KA, pointing to involvement of distinct pathogenesis.
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Background
K eratoacanthoma (KA) is a cutaneous neoplasia arisingpreferably from hair follicle cells on sun-exposed skin
and characterized by self-limiting growth and involution. The
life cycle from origin to spontaneous resolution takes about 4 to
6 months in the majority of cases1 and consists of 3 distinct
stages: proliferative, mature, and involutional. The real nature
of this neoplasma and its relationship to squamous cell carci-
noma (SCC) have been disputed for a long time. Some authors
consider KA as a benign neoplasia, others as a precursor of
SCC,2 others as a well-differentiated variant of cutaneous SCCs
3 or at least an abortive malignancy that only rarely progresses
into an invasive SCC.4 Differential diagnosis between KA and
SCC is challenging due to their similarities and the lack of
reliable diagnostic criteria to distinguish both entities.5
Several studies have attempted to find more specific
methods to distinguish KAs and SCCs accurately. Among them,
Stephenson et al6 studied the expression of p53 protein in KAs
and SCCs and found no clear-cut distinction between these
neoplasms. Kerschmann et al7 analyzed the expression of p53
tumor suppressor protein and the proliferation index (Ki67) in
KAs and SCCs and found that both neoplasms contain stainable
quantities of p53 protein suggesting that these neoplasms are
best viewed as a spectrum. These authors also did not find a
statistically significant difference in proliferation rate between
neoplasms that express p53 and those that do not, for either KA
or SCC.
Kaabipour et al8 studied the expression of p16, a tumor
suppressor protein, in KAs and SCCs and found no significant
differences that could make this marker useful to this differ-
ential.
Kannon et al9 found that the expression of a peanut lectin
receptor is usually uniformly positive in KAs and negative in
the majority of SCCs, indicating that this could aid in the
histologic differentiation of these neoplasms. Takeda et al10
demonstrated differences in the expression of angiotensin type 1
receptors between SCCs and KAs. However, both of these
methods are neither definitive nor reliable to differentiate
KAs and SCCs in all cases.
The study of the microenvironment in neoplasia growth,
invasion, and metastatic potential is of increasing interest
because its stimulatory and restrictive effects upon neoplasm
progression have become evident.11–13 In fact, previous works
have shown that the neoplastic microenvironment plays a major
role in several phases of neoplasm development.14,15 Takahara
et al16 studied the microenvironment of epidermal neoplasmseased macrophages and decreased Lan-
iated with proliferation and invasion of
mors. These authors found a significant
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higher number of dermal macrophages, which are thought to be
associated with angiogenesis in SCC, compared with KA and
other epidermal tumors.
Induction and remodeling of angiogenesis have been
pointed out to be relevant for tumor progression and malig-
nancy.11–13 In fact, angiogenesis has been reported to be an
important prognostic factor of outcome for several malignan-
cies.15,17,18, Differences in microvessel density (MVD) could
also be related to the distinct behavior between KA and SCC
and help distinguish between these entities. Weninger et al19,
however, could not find a significant difference in factor VIII-
determined MVD comparing KAs and SCCs.
CD105 (endoglin) is an 180-kDa homodimeric transmem-
brane protein overexpressed in proliferating endothelial cells.20
The observations that CD105 was strongly up-regulated in the
endothelium within various tumors compared with normal
tissues supported the important role of CD105 in the investi-
gation of tumor angiogenesis.21–23 CD105 has been demon-
strated to be an endothelial cell proliferation-associated marker
and to represent a powerful indicator of neovascularization.20
To the best of our knowledge, CD105-determined MVD has not
been studied in KAs.
Hypotheses and Specific Objectives
To investigate whether the assessment of MVD could be
helpful in KA and SCC differential diagnosis and to gain insight
into the pathogenesis of KA-like neoplasms, we compared the
density of CD105 and CD34 stained vessels in KAs and SCCs
and their relation to the expression of the p53 oncoprotein and
the proliferation marker Ki67.
METHODS
Study Design
This is an observational retrospective cohort study.
Patients and Material
This study has been approved by the Research Ethics
Committee of the State University of Campinas (ID number
822/2005).
Routinely, formalin-fixed and paraffin embedded speci-
mens of 43 KA-like lesions from 41 patients were selected from
the files of the Department of Pathology, State University of
Campinas (UNICAMP). These cases corresponded to the cohort
of a previous study 24 in which we analyzed the histopathologic
features associated with clinical regression in KA-like lesions.
In brief, during a period of 4 years, when a patient with a
cutaneous KA-like lesion (firm, dome-shaped, smooth, enlar-
ging papule or dome-shaped nodule with a central umbilicated
keratinous core) was referred to the dermatological outpatient
center, the following routine was taken by the same dermatol-
ogist (RFM): cutaneous examination findings were recorded;
photos were taken and a partial biopsy was performed so as to
include its center and side throughout its depth, to allow the
evaluation of the neoplasia architecture and the bottom neo-
plasia border. A follow-up appointment was scheduled 1 month
later for clinical re-evaluation by the same dermatologist as well
as lesion measurement and definition of treatment modality. In
cases of growing (progression, infiltration and lack of involu-
Watanabe et altion) or minimally regressing lesions, complete surgical exci-
sion, as for SCC, was done. In contrast, involuting lesions were
left untreated. The patients’ ages ranged from 27 to 93 (mean
2 | www.md-journal.com71.5) years and the lesions diameter ranged from 5 to 40 (mean
19) mm.
After combined clinical, histological, and follow-up evalu-
ations, 32 of 43 lesions were assessed as KA and 11 as SCC
(aggressive course and histological features of SCC). Twelve
KAs were partially excised (first biopsy) in the intermediate
stage between proliferative and fully developed, and 20 in the
intermediate stage between the fully developed and regressing
phase. An additional 3 lesions were excluded from the present
study because of lack of sufficient material to perform immuno-
staining.
No lesions with obvious clinical signs of involution at
presentation nor special morphologic or syndromic types of
KAs were included. No recurrence or metastasis developed after
a follow-up of 3 months to 10 years.
Immunohistochemical Staining
The biopsies of all 40 lesions (29 KAs and 11 SCCs) were
formalin-fixed. Sections (4-mm thick) were cut from the
retrieved neoplasm blocks, dewaxed, and rehydrated in graded
ethanol. The primary antibodies used were either p53 (D07;
DakoCytomation, Glostrup, Denmark) at a dilution of 1:100,
Ki67 (mib1; Dako) at a dilution of 1:150, or CD34 (NCL-END,
Novocastra, Newcastle upon Tyne, UK) at a dilution of 1:100 or
CD105 (SN6 h; Dako) at a dilution of 1:10. For all antibodies
with the exception of CD105, a steamer was used for epitope
retrieval with either citrate buffer (CD34) or Tris-ethylenedia-
minetetraacetic acid (EDTA) buffer (p53 and Ki67). For CD105,
antigen retrieval was performed using 0.4% pepsin at 37 8C for
30minutes. Only the CD105 sections were incubated at 37 8C
with protein block serum-free (Dako). The EnVision Plus
polymer (Dako) was used as a reaction amplifier. Visualization
of the antibody complex was achieved using 3,3-diaminoben-
zidine tetrahydrochloride according to the manufacturer’s
instructions. Sections were counterstained with hematoxylin.
Appropriate controls were included in each assay. For negative
controls, primary antibodies were omitted and the specimens
were incubated with antibody diluent. Tissue from cutaneous
SCC with optimal fixation and blocking was used as positive
control.
Microvessel Quantification
The sections were blindly scanned at low magnification
(100) by a single pathologist for areas of highest microvessel
density), so-called ‘‘hot spots.’’25 For each section, starting at
the area assumed as the ‘‘hot spot,’’ 10 images of consecutive
high-power fields were obtained using a E200 Nikon micro-
scope equipped with a A630 Canon camera, both for CD34 and
CD105. When the size of the biopsy did not allow the capture of
10 different images, all distinct fields were photographed. Areas
along the border between neoplasm and surrounding tissue were
preferred, whereas areas next to hair follicles were avoided. Any
brown-stained single cells or clusters of cells, which were
separated from other stained areas, were considered a single
countable vessel. Unstained lumina were not taken into account.
For each image, the total stromal area was calculated using
computer-assisted image analysis (Imagelab analysis software,
2000), which allows manual segmentation of target areas. The
stromal areas measured up to 0.04mm2 in each digital image.
Medicine  Volume 94, Number 23, June 2015MVD was defined as the number of manually counted stained
vessels per mm2 (v/mm2). The MVD of the most vascularized
area of each section and the MVD corresponding to the sum of
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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lated (total MVD).
p53 and Ki67 Quantification
As for the vascular markers, the sections stained with p53
and Ki67 were blindly scanned for ‘‘hot spots’’ and10 images
of consecutive high-power fields were obtained according to the
size of the biopsy. A quantitative analysis of the expression of
each marker was performed using computer-assisted image
analysis (Imagelab analysis software, 2000). All positive and
negative nuclei of epithelial neoplasm cells were counted in
each image. The neoplasm expression of these markers was
calculated as the percentage of positive cells in the most positive
area as well as the percentage of positivity corresponding to the
total amount of nuclei counted per section.
Statistical Analysis
The data obtained from the incisional biopsies of the 40
KA-like lesions were analyzed (KM and ICW). The CD34 and
CD105-determined MVD and the p53 and Ki67 expression
percentage were calculated with Winstat 3.1 software. Normal
distribution of the variables was tested according to Kolmo-
gorov–Smirnov. Student t test was used to evaluate differences
between both groups. Correlations among the variables were
assessed by Pearson correlation coefficient analysis. In addition,
multiple liner regressions were calculated, which enables us to
determine whether correlations are independent. Moreover, we
calculated the coefficients of determination R2. The significance
level was 0.05.
RESULTS
The study comprised 29 KAs and 11 SCCs, which had been
classified primarily according to clinical follow-up.
CD34 and CD105 antibodies provided a uniform and
moderate (CD105) to intense (CD34) membrane staining of
endothelial cells with no or very low background (Figure 1A-
D). Immunohistochemical detection of p53 and Ki67 proteins
Medicine  Volume 94, Number 23, June 2015was characterized by nuclear staining that varied in intensity but
was comparable to positive controls (Figure 2A-D). In the
Kolmogorov test, all examined variables showed a close
FIGURE 1. Immunostaining of microvessels using CD105 in KA
(A) and SCC (B). CD34 membrane staining of endothelial cells in
KA (C) and SCC (D). Original magnification: 400.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.approximation to the normal distribution, thus confirming the
use of parametric tests.
There were no statistically significant differences between
KAs and SCCs in microvessel density revealed by CD34
(P> 0.2) or CD105 staining (P> 0.2), as well as the density
of p53 positive nuclei (P> 0.2). The Ki67 staining index was
significantly higher in SCCs (P¼ 0.0058) (Figure 3). SCCs
were also compared with each KA phase by analysis of var-
iance, followed by the least significant difference post-hoc test.
Correlations among the variables were assessed by Pearson
correlation coefficient analysis. As potential differences
between the different KA phases could provoke pseudo corre-
lations, we also calculated partial regressions with the variable
‘‘KA phase.’’ There were significant differences in Ki67 stain-
ing index (P¼ 0.005) between the groups. The lowest values
were found in the fully developed/regressing KAs, followed by
the proliferative/fully developed KAs, and the highest values
were found in SCCs. The post-hoc test showed only significant
differences between the regressing KAs and SCCs. There was,
however, considerable overlap between the values in the
3 groups.
In SCCs, there were no significant correlations between the
density of CD105-positive vessels and age, neoplasm size,
Ki67, or p53 index (P> 0.2 for all). We found a positive
correlation in KAs between the CD105 density and the Ki67
index (r¼ 0.43; P¼ 0.019; Figure 4A). This was not the case for
SCCs (Figure 4B). In a multiple linear correlation for CD105-
MVD in KAs, the Ki67 index remained as an independent
variable (P¼ 0.004; R2¼ 0.31), whereas in multiple linear
correlation for SCCs, this result was not found.
We did not find any significant correlation for KAs
between the size of the neoplasm and patient’s age, Ki67, or
p53-index (P> 0.2 for all). However, in SCCs, there were
significant positive correlations between the neoplasm size
and p53 index (r¼ 0.59, P¼ 0.05) and the neoplasm size and
age (r¼ 0.617; P¼ 0.043), which demonstrated independence
in a multiple linear regression (Figure 5).
FIGURE 2. Diffuse nuclear p53 immunostaining in KA (A) and
SCC (B); Ki67 immunostaining in KA (C) and SCC (D). Original
magnification: 400.DISCUSSION
KA is a squamous proliferative lesion, which has become a
neoplasm of great interest in the study of carcinogenesis
www.md-journal.com | 3
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ship to SCC. The reason for the distinct biological behavior
between these neoplasms is not yet understood.
Angiogenesis is considered to play a major role in neo-
plasm progression, as neoplasm growth is dependent on a
sufficient supply of nutrients and oxygen.26 In contrast to
SCC, a malignant tumor with metastatic potential, KA does
not metastasize. Weninger et al19 investigated MVD in basal
cell carcinomas (BCCs), SCCs, and KAs and found that the
vascular density was significantly lower in BCC than in both
KA and SCC, but no significant difference in MVD was
demonstrated between the latter neoplasms. Our results are
in accordance with their findings because the assessment of
MVD using both a pan-endothelial marker (CD34) and a
neovascularization marker (CD105) did not reveal statistical
differences between them. We share the opinion of these
authors that neoplasm MVD probably does not reflect the
neoplasm progression differences between them.
Our quantitative data from the proliferation rate (Ki67) did
show discriminating power between KAs and SCCs, with a rate
FIGURE 3. Expression of Ki67, p53, CD34, and CD105 in keratoa
differences between KAs and SCCs regarding the CD34 or CD105 m
was significantly higher in SCCs.significantly higher in SCCs. However, there was a large
overlap between both groups, making it difficult to apply in
routine practice because pathologists most commonly use
FIGURE 4. Significant positive correlation of MVD-CD105 and Ki67-p
4 | www.md-journal.comsemiquantitative methods of evaluation. Still, is of interest that
the SCCs, neoplasm with a higher malignant potential than
KAs, had the higher proliferation rate. With respect to the time
of neoplasm growth, it is known that KAs generally grow faster
than most SCCs, which seems to conflict with the proliferation
rate found by our study. This can be explained by the fact that
part of our KAs was in the intermediate stage between the fully-
developed and regressing phases. Indeed, when SCCs were also
compared with each KA phase by the post hoc test, significant
differences were only found between the regressing KAs and
SCCs. Our other quantitative data did not show discriminating
power between KAs and SCCs, adding to the hall of similarities
previously described for these 2 neoplasms.
The immunostains assessed in our study demonstrated
important differences regarding neoplasm pathogenesis.
Although neoangiogenesis (CD105-MVD) in KAs was associ-
ated with neoplasm proliferation, in SCCs, it was not. It is
probable that KA needs neovascularization to grow and SCCs
have independent growth, probably due to genetic differences.
Waring et al27 found rarity of loss of heterozygosity in KAs, in
thomas and squamous cell carcinomas. There were no significant
ovessel density nor the p53þ cells density. The Ki67 staining indexcontrast with what was described for SCCs. In Clausen et al’28
study, KA showed a surprisingly high degree of genetic imbal-
ance. Many of the most frequently found aberrations in KAs
roliferation index in KAs (A). This was not the case for SCCs (B).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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could be linked to their peculiar rapid growth followed
by regression.
In addition, the correlations observed between age and
neoplasm size or p53 expression and neoplasm size in SCCs but
not in KAs also indicate further different mechanisms of
progression for each neoplasm.
We consider that the strengths of this study are as follows:
the diagnoses of SCC and KA were established on clinical/
pathological/follow-up basis; the lesions were relatively
uniform in size and the patients’ ages relatively uniform, in
each group. To the best of our knowledge, this is the first
systematic study on angiogenesis of lesions with clinical
appearance of KA in which, to improve the histopathologic
criteria that discriminate the 2 neoplasms, clinical evolution was
used as gold standard. However, the small sample size for KA-
like SCCs may have restricted the test power for this group and
is a limitation of our study.
In summary, from our results, we may conclude that KA
and SCC have similarities, as CD105- and CD34-MVD. How-
ever, the low Ki67 proliferation index and the positive corre-
lation between Ki-67 index and neovascularization on KA
suggest dependence in neovascularization to grow in KA,
pointing to involvement of distinct pathogenesis.
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